The NCITA adopted study ARCADIAN (Atovaquone with Radical ChemorADIotherapy in locally Advanced Non-small cell lung cancer) is a Phase 1 study investigating whether the antimalaria drug Atovaquone, combined with chemoradiotherapy, can improve the effects of treatment in lung cancer patients. ARCADIAN is a follow-on clinical trial from the ATOM trial, which reported that Atovaquone can reduce tumour hypoxia by 55% in patients with non-small cell lung cancer by reprogramming tumour metabolism.
The ARCADIAN study team is delighted to have completed recruitment with 20 patients recruited at its 3 participating sites: the Churchill Hospital, Oxford University Hospital NHS Trust and the Western General Hospital, NHS Lothian, Scotland and Guy’s Hospital, Guy’s and St Thomas’s NHS Foundation Trust. This important milestone will enable researchers to establish the maximum tolerated dose of Atovaquone that can safely be combined with chemoradiotherapy to see if it does indeed improve the effects of treatment in patients with non-small cell lung cancer. Tumour hypoxia responses to Atovaquone will be assessed using 18F Misonidazole positron emission tomography/computed tomography (PET/CT) imaging.
The ARCADIAN study is led by Professor Geoff Higgins, and sponsored by the University of Oxford. The study is also supported by the National Cancer Imaging Translational Accelerator (NCITA) Repository Unit which provides secure storage and sharing of patient datasets between the clinical sites. This includes PET/CT research images, prior CT imaging as well as PET imaging raw data.
To read more about the ARCARDIAN study, see the Oncology Clinical Trials Office (OCTO) ARCARDIAN Study webpage.